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INTRODUCTION
Telomerase activity is frequently detected in most malig-
nant tumors, but not in premalignant lesions or in normal
tissues. Therefore, most of telomerase studies have used the
telomerase assay as a complementary method to distinguish
between benign and malignant tumors, and telomerase activ-
ity is widely accepted as a potential marker of tumor biolo-
gy (1, 2). Detection of telomerase activity can be used for
early diagnosis of cancer, in combination with the tradition-
al cytology (3), and also has been proposed as a predictor of
poor clinical outcome of cancer patients (4). In addition,
telomerase activity was used as a marker for residual or re-
currence of tumor (5). Recently, there is increasing evidence
that telomerase activity is associated with cell proliferation
without malignancy (6-9). Skin samples that had low levels
of telomerase activity  and uroepithelial cells that had no
detectable telomerase activity were shown to have greatly
elevated levels of telomerase activity when these cells were
cultured (10, 11). So, it has been suggested that telomerase
activity is a biomarker of cell proliferation, not of malignant
transformation (11). At present, however, there is little in-
formation about the telomerase activity in nonmalignant,
chronic hyperproliferative skin diseases and its relationship
with cell proliferation.
Psoriasis is a pathologic condition in which hyperprolifer-
ation of keratinocytes with an increase in stem cells and
transient amplifying cells is one of the characteristic features
(12), and retinoic acid (RA) is a commonly used antiprolif-
erative agent for the treatment of this disease. Therefore,
using telomeric repeat amplification protocol (TRAP) assay,
the current study was designed to investigate telomerase
activity in lesional skin of psoriasis and correlation between
telomerase activity and Ki-67 expression, a cellular prolifer-
ation marker. The effect of RA on the expression of telom-
erase activity in HaCaT cells, which are commonly used as a
model for highly proliferative epidermis, was also investi-
gated. In the present study we demonstrated that telom-
erase activity was increased in lesional skin of psoriasis in
association with increased Ki-67 labelling index, represent-
ing another example showing telomerase activity correlates
with cellular proliferation. Telomerase activity in HaCaT
cells was suppressed by RA.
MATERIALS AND METHODS
Tissue specimens
Lesional and nonlesional skin samples, which were sepa-
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Detection of Telomerase Activity in Psoriasis Lesional Skin and
Correlaton with Ki-67 Expression and Suppression by Retinoic Acid
Telomerase activity is usually detected in most tumor tissues but not in normal
tissues. Recently, there is increasing evidence that telomerase activity is associ-
ated with cell proliferation without malignancy, whereas there is little information
about telomerase activity and its relationship with cell proliferation in chronic
hyperproliferative skin diseases. Thus, we studied telomerase activity in skins
from 10 patients with psoriasis and compared telomerase activity with the
expression of Ki-67, a proliferation marker, using immunohistochemical staining.
The effect of retinoic acid on the telomerase activity in HaCaT cells was also
evaluated. Telomerase activity was detected in 7 (70%) of 10 lesional skins of
psoriasis and none of the nonlesional skin. Telomerase activity in lesional skin
was significantly associated with Ki-67 labelling index. Retinoic acid treatment on
HaCaT cells inhibited telomerase activity, which correlated with inhibition of cell
proliferation by the agent. The results of our study represent another example
that shows telomerase activity correlates with cellular proliferation. Further stud-
ies on the regulation of the telomerase are needed to understand the cellular fac-
tors involved in controlling telomerase activity. 
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rated at least 10 cm from each other and located on sun-pro-
tected area, were obtained from 10 psoriasis patients with a
4-mm punch biopsy. Lesional skin samples were obtained
in duplicate, with one submitted for routine histology and
immunohistochemistry and the other placed into a 1.5-mL
microcentrifuge tube for assay of telomerase activity. None
of the patients received systemic therapy before the collec-
tion of skin samples. Specimens were stored at -80℃ until
the analysis of telomerase activity.
Cell line and culture conditions
HaCaT cells were kindly provided by Dr. NE Fusenig
(DKFZ, Heidelberg, Germany) and cultured on the Dulbec-
co’ s modified Eagles medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 100 units/mL penicillin,
and 200  g/mL streptomycin at 37℃ with 5% CO2 in
humidified air. All-trans RA (Sigma Co., St. Louis, U.S.A.)
was diluted in dimethyl sulfoxide (DMSO) to a stock of 10-4
M. The stock was diluted in a culture medium to prepare
various concentrations of RA. When cells were treated with
RA, they were protected from light during the incubation
period. HaCaT cells were seeded at a density of 1×106 cells/
mL in DMEM in six-well culture plates. After 24 hr, the
medium was replaced by culture medium supplemented
with 10-6, 10-8, and 10-10 M RA or without RA supplemen-
tation. After 5 days, cells were then harvested from the cul-
ture plates by trypsin/EDTA treatment and the cell num-
bers were determined by using hemocytometer. The cells
were aliquoted (105 cells), centrifuged, placed in 1.5-mL
microcentrifuge tubes, and stored as pellets at -80℃ until
analyzed by TRAP assay.
Preparation of tissue and cells for telomerase activity
analysis
Tissue specimens were cut into slices and these slices (40-
100 mg) were transferred to a sterile 1.5-mL microcentrifuge
tubes containing 200  L of 1×CHAPS lysis buffer (10 mM
Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM
benzamidine, 5 mM mercaptoethanol, 0.5% CHAPS, 10%
glycerol) for telomerase extraction. Then these mixtures
were dispersed by homogenization with disposable pestles
attached to a Pellet Pestle Motor (Kontes Co., U.S.A.) for 10
sec. Pellets of HaCaT cells (105 cells) were also resuspended
in 200  L of 1×CHAPS lysis buffer and homogenized.
Homogenized tissues and cells were then left on ice for 30
min and centrifuged at 12,000 g for 20 min at 4℃. Super-
natants were collected and the protein concentrations were
measured using BCA protein assay kit (Biorad Co., Her-
cules, U.S.A.). When performing the TRAP assay, 2  g of
protein was analyzed according to the manufacturer’ s
instruction.
Telomerase activity assay
Telomerase activity was measured using TRAP assay with
TRAPEZE Telomerase Detection Kit (Oncor, Geithersburg,
U.S.A.). Before polymerase chain reaction (PCR), 5′ -end-
labeling of the TS primer was done in a total of 20  L mix-
ture containing 2.5  L of  -32P-ATP (3000 Ci/mmol, 10
mCi/mL), 10  L of TS primer (5′ -AATCCGTCGAGCAG
AGTT-3′ ), 2  L of 10×Kinase buffer, 0.5  L of T4 Polynu-
cleotide kinase (10 U/ L), and 5  L of distilled water. This
mixture was incubated for 30 min at 37℃, and then 5 min
at 85℃. In 0.2 mL tubes, an extract containing 2  L (1  g/
L) of protein was assayed in 50  L of reaction mixture (5  L
10×TRAP buffer [200 mM Tris-HCl, pH 8.3, 630 mM
KCl, 15 mM MgCl2, 1 mM EGTA, 0.5% Tween 20], 1  L
50×dNTPs mix [25 mM each dATP, dTTP, dGTP and
dCTP], 2  L 32P-TS primer, 1  L TRAP primer mix [RP
primer, K1 primer, TSK1 template], 0.4  L Taq polymerase
[5 U/ L], and 38.6  L distilled water). The reaction mixture
was incubated at room temperature for 30 min to allow
telomerase to extend TS primer and heated to 94℃ for 3
min to inactivate telomerase, and then followed by 30 cycles
(94℃ for 30 sec and 59℃ for 30 sec) of PCR amplification
of the telomeric products with GeneAmp Thermal Cycler
Model 2400 (Perkin-Elmer, Foster, U.S.A.). Analyses of 25
L of the PCR products were performed on 12.5% nonde-
naturing polyacrylamide gels. Gels were exposed to phos-
phor screens overnight, and were visualized on a Phospho-
Imager using MicroAnalyst software (Biorad Co.). Hu-man
embryonic kidney 293 cells were used as positive control.
For negative control, samples were incubated at 85℃ for
10 min prior to the TRAP assay to inactivate telomerase or
water instead of extracts used as a template for PCR. All
TRAP assays for every conditions were performed at least
twice, with comparable results between trials.
Immunohistochemistry
Paraffin-embedded blocks of 10 skin lesions of psoriasis
were used for immunohistochemistry to detect Ki-67 anti-
gen. Ki-67 immunohistochemistry using the monoclonal
antibody MIB1 (DAKO, Carpinteria, U.S.A.) and LSAB
(labelled streptavidin biotin) kit (DAKO) was performed
according to the manufacturer’ s instructions following anti-
gen retrieval with microwaves. Cut sections were then im-
munostained with MIB1 (diluted 1:500) for 1 hr at room
temperature, incubated with biotinylated anti-mouse sec-
ondary antibody for 30 min, followed by incubation with
streptavidin peroxidase and staining with AEC chromogen.
Labelling index (LI) was expressed as the number of positive
cells/total number of epidermal cells (basal and suprabasal)
×100%. Five high power fields (×400 magnification)
were counted in each sample. The skin lesions of psoriasis
were divided into telomerase-positive and telomerase-nega-Telomerase Activity in Psoriasis Lesional Skin 625
tive lesions and the association between telomerase activity
and Ki-67 labelling index was analyzed using paired t-test.
Values were expressed as mean percentage±standard error
of the mean (SEM) and p value<0.05 was considered signif-
icant.
MTT assay
Cellular growth in the presence or absence of RA was
determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay. HaCaT cells
were inoculated at the concentration of 1×104 cells into
96-well microtiter plates. After overnight culture, RA was
applied at a final concentration of 10-6, 10-8, and 10-10 M in
triplicate culture wells, and cultures were incubated for 5
days at 37℃. On the 5th day after the application of RA,
100  L of MTT (1 mg/mL) was added to each well. After 4
hr incubation at 37℃, the reaction was terminated by
removing the supernatant and the dye was dissolved by
adding 100  L DMSO, followed by a thorough mixing.
The plates were read at 570 nm on an ELISA reader (BIO-
RAD, U.S.A.). The mean and standard deviations were
derived from six replicates
Quantitation of telomerase activity
Individual bands of TRAP assay performed on HaCaT
cells treated with RA were quantitated by PhosphoImager
using MicroAnalyst  software (BIORAD Co.). To compare
relative amounts of telomerase activity between samples,
the TRAP assay signals of the telomerase ladder were nor-
malized to that of the internal standard. The signal intensity
of the bands from RA-treated samples was compared with
that from the untreated, control sample and expressed as a
percentage of the telomerase activity detected in untreated
cells. All results were expressed as mean±SEM. The statis-
tical significance of differences between the measured telom-
erase activity after the addition of the RA was determined
by means of the Kruskal-Wallis test. The p value<0.05 was
considered statistically significant.
RESULTS
Telomerase activity was detected in lesional skin but
not in nonlesional skin of psoriasis
To demonstrate whether telomerase activity is involved in
psoriasis skin, we assayed the telomerase activity in lesional
and nonlesional skins of psoriasis. Using TRAP assay, telom-
erase activity was detected in 7 (70%) out of 10 lesional skins
of psoriasis. None of the nonlesional skin had detectable
telomerase activity. Telomerase activity of lesional skin was
clearly increased compared with that of nonlesional skin,
but TRAP assay revealed only a few ladders of telomerase
products in lesional skin of psoriasis, indicating a relatively
low level of telomerase activity or dilution of telomerase
activity by telomerase-negative cells (Fig. 1). As controls, 2
normal skins obtained from patients undergoing plastic
surgery were tested for telomerase activity and telomerase
activity was not detected.
Correlation between telomerase activity and Ki-67
expression in lesional skin of psoriasis
As we found that most psoriasis lesional skins had increased
telomerase activity and some lesional skins did not show
telomerase activity, we performed immunohistochemical
staining using monoclonal antibody MIB1 in telomerase-
positive and -negative lesional skins to determine whether
telomerase activity correlates with the proliferative state of
the lesional epidermal cells. Ki-67-positive cells were dis-
tributed in the basal and a few suprabasal cells mostly along
the lower parts of the rete ridges of the lesional epidermis
(Fig. 2). Mean LI of Ki-67 expression was calculated as 19.9
±5.7% in telomerase-positive psoriasis lesions (n=7) and
10.1±2.8% in telomerase-negative psoriasis lesions (n=3).
LI of Ki-67 expression in telomerase-positive lesions was
significantly higher than that in telomerase-negative lesions
(p<0.05),  suggesting a significant association between
telomerase activity and Ki-67 expression in psoriasis lesions
(Fig. 3).
50 bp
36 bp
Fig. 1. Telomerase activity is detected in lesional skin of psoria-
sis, but nonlesional skin has barely detectable telomerase activi-
ty. Bottom line represents 36 bp internal control (S-IC) and lad-
ders represent 6 bp repeats starting with 50 bp. C, negative
control; P, positive control; L, lesional skin of psoriasis; N, non-
lesional skin of psoriasis.
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Suppression of telomerase activity in HaCaT cells by RA
To reveal whether RA can inhibit telomerase activity,
HaCaT cells which are known to express high levels of
telomerase activity (13), were treated with RA and assessed
for telomerase activity. Telomerase activity was markedly
down-regulated in HaCaT cells treated with varying con-
centrations of RA for 5 days (Fig. 4). A decline of telom-
erase activity in RA-treated versus untreated cells was
observed in a dose-dependent manner as follows: relative
telomerase activity (mean±SD) was 74.1±3.2% at 10-10 M
of RA, 54.1±9.2% at 10-8 M of RA, and 27.2±7.2% at
10-6 M of RA compared to the untreated cells (Fig. 5). Sig-
nificant suppression of telomerase activity in HaCaT cells
A B
Fig. 2. Telomerase activity-positive lesional skin of psoriasis (A) reveals increased expression of Ki-67, keratinocyte proliferation mark-
er, compared to telomerase activity-negative lesional skin of psoriasis (B). Note that Ki-67-positive cells are predominantly localized in
the basal and first few suprabasal layers (immunohistochemical stain,×200).
Telomerase Activity
Fig. 3. Ki-67 labelling index is significantly higher in telomerase
activity-positive psoriasis lesional skin than in telomerase acti-
vity-negative psoriasis lesional skin (*p<0.05).
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Fig. 4. Suppression of telomerase activity in HaCaT cells treated
with varying concentrations of retinoic acid as measured by the
TRAP method. Telomerase activity declines in a dose-dependent
manner. Bottom line represents 36 bp internal control (S-IC). 
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was observed at 10-8 M and 10-6 M of RA (p<0.05).
Correlation between inhibition of telomerase activity
and cell proliferation by RA
To investigate whether the decreased telomerase activity
observed during the treatment with RA correlates with in-
hibition of cell proliferation by RA, MTT assay was per-
formed. MTT assay showed a dose-response relationship for
inhibition of HaCaT cells proliferation by RA concentrations
of 10-10, 10-8, and 10-6 M. HaCaT cells showed a decrease of
proliferation during the 5 days of exposure to RA, and rela-
tive proliferative activity (mean±SD) was 87.5±5.4% at
10-10 M of RA, 80.3±5.6% at 10-8 M of RA, and 54.3±
8.9% at 10-6 M of RA compared to the untreated cells (Fig.
5). Significant inhibition of proliferation was attained at
10-6 M of RA (p<0.05). The lesser degree of decline in telom-
erase activity at the lowest RA dose for the inhibition of
proliferation and the higher degree of decline at the highest
dose of RA suggest a link between the proliferation and
telomerase regulation.
DISCUSSION
Telomerase activity has been shown to be specifically ex-
pressed in most human cancers and immortalized cell lines
(1, 14) but is lacking in normal somatic cells except for
germline cells of testis or ovary, and hemopoietic stem cells
(6, 15), which have been shown to express low levels of
telomerase activity. Besides these cells, telomerase activity
was demonstrated in proliferative basal layer of epidermis
(10), endometrial tissue during the proliferative phase of
the menstrual cycle (16), and highly proliferative normal
oral mucosa (17). Telomerase activity was also detected in
normal proliferating human uroepithelial, mammary, and
prostate epithelial cultures, but not in uncultured or senes-
cent cells (11). Detection of telomerase activity in these nor-
mal proliferating somatic cells suggests that telomerase
activity is associated not only with tumorigenic transforma-
tion but also with the proliferation state of the cells (11). In
addition, telomerase activity is increased in blood lympho-
cytes from atopic dermatitis patients and correlates with
cellular proliferation (9). In normal tissues like fibroblasts in
which proliferation is generally absent, telomerase activity
to maintain the tissue integrity is not required (10). Recent
studies also strongly suggest that telomerase activation may
be responsible in part for some of nonmalignant prolifera-
tive skin diseases (18-20). The level of telomerase activity in
nonmalignant skin diseases was much lower than that of
malignant skin tumors (20). This can be interpreted as that,
unlike malignant tumors in which most of cells express
telomerase activity, only a subset of cells in nonmalignant
proliferative diseases express telomerase activity, because the
level of telomerase activity can be influenced by the propor-
tion of telomerase-positive cells in the tissues, namely the
dilution effect by the telomerase-negative cells or stroma
(10). Thus, it may be speculated that the detection of the
low level of telomerase activity in lesional skin of psoriasis,
but not in normal skin in the present study results from
selective expansion of a subset of cells expressing telomerase
activity.
For cell proliferation in the epidermis, the transition from
quiescent (G0/early G1 state) stem cell to proliferative tran-
sient amplifying cell is required (7). In psoriasis, six- to
seven-fold more stem cells than in normal epidermis have
emerged from its normal G0 state into active cell cycle state
to become transient amplifying cells (12). In addition, it has
been suggested that telomerase is not an epidermal stem
cell marker and the more actively proliferating transient
amplifying cells exhibit more telomerase activity than epi-
dermal stem cells (21). Therefore, telomerase activity in
psoriasis observed in this study may result not only from
stem cells but also from selective expansion of telomerase-
positive cells such as expansion of transient amplifying cells.
In situ hybridization study to detect human telomerase
RNA (hTR) also revealed moderate to strong levels of hTR
in cells of the expanded rete ridges of active psoriasis and it
was suggested that the increased hTR expression in supra-
basal epidermal cells could be due to the migration of
expanded proliferating keratinocytes into the suprabasal
compartment (19). Another possible candidate responsible
Concentrations of RA
Fig. 5. Relative telomerase activity and cell proliferation by MTT
assay in varying doses of retinoic acid (RA)-treated and control
HaCaT cells. Inhibition of telomerase activity in HaCaT cells
treated with RA for 5 days is in parallel with inhibition of cell pro-
liferation (*p<0.05). Relative telomerase activity during RA treat-
ment is expressed as a percentage of the telomerase activity
detected in untreated cells.
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for telomerase activity in psoriasis lesion is leukocyte infil-
trates in the skin. Leukocytes have been shown to constitu-
tively express low levels of telomerase activity (6), which
can be increased with antigen stimulation (6, 20), and are
known to play a critical pathogenic role in psoriasis. There-
fore, the increased level of telomerase activity observed in
psoriasis may be in part due to telomerase activity expressed
by leukocytes themselves (19, 20). However, the levels of
telomerase activity in lesional skin of psoriasis did not cor-
relate with the degree of inflammatory cell infiltrate (20)
and hTR was not expressed in infiltrating lymphocytes in
active psoriasis (19).
Immunohistochemistry using monoclonal antibody to
Ki-67 nuclear antigen is a useful method for the detection
of proliferating cells in tissue samples (22). As Ki-67 expres-
sion correlates well with growth fraction of cells and rapidly
proliferating cells require telomerase in order to maintain
chromosomal stability, telomerase expression might corre-
late with Ki-67 expression. Mokbel et al. (23) reported that
telomerase activity was significantly associated with Ki-67
expression in breast cancer, suggesting an association with
cellular proliferation. Poremba et al. (24) also reported a
positive correlation between the mean value of MIB1 immu-
noreactivity and telomerase levels. The MIB1 proliferation
index ranged from 12% for low-telomerase tumors to 63%
for high-telomerase tumors. Malignant melanomas also
showed high telomerase activities correlated with cellular
proliferation as measured by Ki-67 index (2, 25). In addi-
tion, the distribution of hTR and Ki-67 was also similar in
newborn foreskins, basal cell carcinomas, and squamous cell
carcinomas, suggesting that the expression of hTR correlates
with the proliferative state (19). It is known that telomerase
activity (26) and expression of Ki-67 antigen (22) are high
in both S and M phases of cell cycle. Therefore, in telom-
erase-negative psoriasis lesion with a low level of Ki-67
expression shown in the present study, there is a possibility
that epidermal cells bearing proliferative potential might be
mainly in resting G0/G1 phase at the time of examination,
and thus might exhibits little telomerase activity and not
express Ki-67 antigen.
RA is a known modulator of cell proliferation and differ-
entiation. In several cell lines, RA inhibited telomerase activi-
ty by inducing cellular differentiation and inhibiting cell
proliferation (27, 28). In case of HaCaT cells, treatment
with higher doses (above 10-7 to 10-6 M) of RA significantly
reduced cellular growth by increasing premature shedding
of cells into the culture medium and by inducing an inhibi-
tion of differentiation (29, 30). This resulted from a marked
reduction in the number of desmosomes with complete dis-
appearance of their ultrastructual components (30). These
results suggest that inhibition of telomerase activity in Ha
CaT cells by RA, unlike in other immortal cell lines in
which RA-induced differentiation resulted in a decrease of
telomerase activity (27, 28), be related to the inhibition of
proliferation but not to the induction of differentiation. In
the present study, to further analyze the relationship between
cell proliferation and telomerase activity, HaCaT cells grown
with RA were tested by MTT assay. The inhibition of pro-
liferation by RA closely paralleled the inhibition of telom-
erase activity by this agent, further suggesting that telom-
erase expression be linked to cell proliferation. Therefore, it
may be speculated that one possible mechanism of epider-
mal hyperplasia in psoriasis might be the increased telom-
erase activity in psoriatic epidermis, and RA exerts its anti-
proliferative activity by suppressing telomerase activity.
The exact biological significance of telomerase activity in
psoriasis remains to be determined. Further studies on the
regulation of the telomerase are needed to understand the
cellular factors involved in controlling telomerase activity.
A better understanding of these factors will be important to
provide a new insight on the therapy of this chronically an-
noying disease.
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